Amarin Announces Completion of Dosing in a Fixed-Dose Combination Study With Vascepa(R) and a Leading Statin

Amarin Announces Completion of Dosing in a Fixed-Dose Combination Study With
Vascepa(R) and a Leading Statin

BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 17, 2012 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced today that it has completed dosing and
pharmacokinetic sampling in a study to test a fixed-dose combination of
Vascepa^® (icosapent ethyl) capsules and a leading statin. The clinical name
for this combination product is AMR102. Prior to commencement of the study,
Amarin opened an Investigational New Drug Application (IND) with the U.S. Food
and Drug Administration which became effective after the standard 30-day

The purpose of this AMR102 study is to determine the bioavailability of the
EPA (eicosapentaenoic acid) and statin components when taken as a fixed-dose
combination product, relative to the individual reference agents taken
concomitantly. Statin bioavailability from both the fixed-dose and concomitant
regimens will also be compared with that from the reference statin taken alone
in healthy subjects.Additionally, pharmacokinetic data from this study will
be examined to explore relationships between in vitro dissolution data and in
vivo pharmacokinetic data. The study is designed as a randomized, open-label,
multiple dose, parallel-group study in 48 healthy subjects conducted at a
single site in the United States.

"This study is aimed at expanding the potential commercial application of
Vascepa by leveraging the clinical successes of the MARINE and ANCHOR trials,
namely effective triglyceride lowering without increasing LDL-C," stated
Joseph Zakrzewski, Amarin's Chairman and Chief Executive Officer. "Amarin's
goal is to identify ways for patients to simplify their lipid management by
developing a single therapy that offers the powerful triglyceride lowering
effects of Vascepa combined with one of the most prescribed statin products."

Amarin looks forward to analyzing the results from this study and expects to
communicate such results in the first half of 2013.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids.Vascepa^® (icosapent
ethyl),Amarin'sfirstFDAapproved product, is a patented, ultra pure omega-3
fatty acid product comprising not less than 96%EPA.For more information
about Vascepa visit For more information about Amarin

The Amarin Corporation plc logo is available at

Forward-looking statements

This press release contains forward-looking statements, including statements
about the potential efficacy, safety and therapeutic benefits of Amarin's
product candidates, clinical trial results, the expecting timing for the
release of clinical results, the clinical importance and impact of Vascepa on
cardiovascular health, Amarin's plan to expand the commercial potential of
Vascepa, and the status of potential future products.These forward-looking
statements are not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to differ
materially from those described or projected herein include the following
uncertainties associated generally with research and development, clinical
trials and related regulatory approvals. A further list and description of
these risks, uncertainties and other risks associated with an investment in
Amarin can be found in Amarin's filings with the U.S. Securities and Exchange
Commission, including its most recent Quarterly Report on Form 10-Q.Existing
and prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.

Amarin'sproduct candidates are in various stages of development and are not
available for sale or use outside of approved clinical trials. Nothing in this
press release should be construed as promoting the use of such product

CONTACT: Amarin Contact Information:
         Stephen D. Schultz
         Senior Director, Investor Relations
         and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (860) 572-4979 x292

company logo
Press spacebar to pause and continue. Press esc to stop.